Subscribe
shutterstock_1935382585_valeriya_zankovych
Valeriya Zankovych / Shutterstock.com
9 March 2023FeaturesBiotechnologySarah Speight

The Dutch non-profit taking on AbbVie for ‘overpricing' Humira by $1.3bn

Big pharma is no stranger to controversy, and AbbVie is perhaps one of the most lambasted.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FTC weighs in on AbbVie antitrust litigation
22 June 2023   Commission argues that a New York federal court erred in its finding that deals between an AbbVie unit and generic manufacturers were justified | US Supreme Court previously ruled that “unjustified” reverse payments can violate the antitrust laws.
Generics
Abbvie seeks to block copycat of endometriosis drug
4 April 2023   Lawsuit is second to be filed in Delaware over Abbvie’s Orilissa treatment | Abbive says Teva’s ANDA infringes patent granted in January.
Big Pharma
Humira: lessons from 20 years of patents, pricing and profits
21 March 2023   As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.


Editor's picks

Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025

Editor's picks

Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025
Americas
LSPN finalists revealed for first-ever US awards
3 March 2025

More on this story

Americas
FTC weighs in on AbbVie antitrust litigation
22 June 2023   Commission argues that a New York federal court erred in its finding that deals between an AbbVie unit and generic manufacturers were justified | US Supreme Court previously ruled that “unjustified” reverse payments can violate the antitrust laws.
Generics
Abbvie seeks to block copycat of endometriosis drug
4 April 2023   Lawsuit is second to be filed in Delaware over Abbvie’s Orilissa treatment | Abbive says Teva’s ANDA infringes patent granted in January.
Big Pharma
Humira: lessons from 20 years of patents, pricing and profits
21 March 2023   As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.

More on this story

Americas
FTC weighs in on AbbVie antitrust litigation
22 June 2023   Commission argues that a New York federal court erred in its finding that deals between an AbbVie unit and generic manufacturers were justified | US Supreme Court previously ruled that “unjustified” reverse payments can violate the antitrust laws.
Generics
Abbvie seeks to block copycat of endometriosis drug
4 April 2023   Lawsuit is second to be filed in Delaware over Abbvie’s Orilissa treatment | Abbive says Teva’s ANDA infringes patent granted in January.
Big Pharma
Humira: lessons from 20 years of patents, pricing and profits
21 March 2023   As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.

More features

Panitch Schwarze hires experienced ex-USPTO examiner
Genmab fights claim over 'secrets theft' behind $1.8bn takeover
Interpreting the SPC manufacturing waiver: EU courts diverge
European court upholds 10x patent after Nanostring appealed injunction
Verily, IBM, litigation funder on the art of leveraging patents
Tempus sues competitor over AI cancer diagnostic tech
Trouble at the USPTO—Part II: Bracing for impact
Fed Circ removes Apple import watch ban threat